NCT03342053View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139)

PHASE2CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

January 2, 2018

Primary Completion Date

October 8, 2019

Study Completion Date

October 8, 2019

Conditions
Huntington's Disease
Interventions
DRUG

RO7234292 (RG6042)

Intrathecal injection

Trial Locations (9)

10117

Charité - Universitätsmedizin Berlin, Campus Charité Mitte; Klinik für Psychiatrie und Psychotherapi, Berlin

44791

St. Josef and St. Elisabeth GmbH ; Klinikum Bochum, Zentralapotheke, Bochum

89081

Universitaetsklinikum Ulm, Ulm

V6T 2B5

The University of British Columbia; The Centre for Huntington Disease, Vancouver

B15 2FG

NIHR Welcome Trust Birmingham CRF - University Hospitals Birmingham; Department of Neuropsychiatry, Birmingham

CB2 0PY

University of Cambridge - John van Geest Centre for Brain Repair, Cambridge

CF24 4HQ

Cardiff University School of Medicine; Institute of Psychological Medicine Clinical Neurosciences, Cardiff

WC1N 3BG

Leonard Wolfson Experimental Neurology Centre, London

M13 9WL

Central Manchester University Hospitals NHS Foundation Trust; Manchester Centre for Genomic Medicine, Manchester

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03342053 - A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7234292 (ISIS 443139) in Huntington's Disease Patients Who Participated in Prior Investigational Studies of RO7234292 (ISIS 443139) | Biotech Hunter | Biotech Hunter